SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,589,443 with 63,351,197,653 in circulation. The last known price of XRP is 1.24455819 USD and is down -0.63 over the last 24 hours. It is currently trading on 1893 active market(s) with $917,900,293.08 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is under pressure amid a broader crypto selloff linked by traders to the Binance hack, while Ripples Swell announcements have drawn disappointment over the tokens muted response. The main debate is whether Ripples partnerships, bank charter and RLUSD growth will create demand for XRP, or primarily benefit Ripple and its stablecoin instead.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is dominated by the midterm elections and Trumps political fortunes, with traders debating how the outcome could affect DJT and broader markets; speculation over Iran-war escalation and oil prices adds to the uncertainty. Sentiment is mostly bearish, with posts citing DJTs sharp decline and weak fundamentals, though some traders anticipate a rebound.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?

Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Biotech Surges as Big Money Backs High-Stakes Kidney Disease Push

The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory pathways responsible for some of medicine's most difficult-to-treat diseases. Among the most closely watched areas is the complement system, a network of proteins that can trigger severe tissue damage when overactivated. With growing interest in kidney disorders and autoimmune diseases, investors are increasingly rewarding companies developing targeted therapies capable of interrupting these pathways with greater precision and fewer side effects.Shares of InflaRx N.V. ...

InflaRx N.V. (NASDAQ:IFRX) Short Interest Update

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 1,809,027 shares, a decline of 26.2% from the March 31st total of 2,452,174 shares. Approximately 3.0% of the company's stock are short...

InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday

InflaRx (NASDAQ:IFRX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-inflarx-stock...

InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer

Oppenheimer initiated coverage on InflaRx in a report on Friday. They set an "outperform" rating and a $5.00 price target on the stock...

InflaRx's (IFRX) "Buy" Rating Reaffirmed at Guggenheim

Guggenheim reiterated a "buy" rating and set a $14.00 price target on shares of InflaRx in a report on Tuesday...

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy ratin...

InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Should You Buy?

InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Still a Buy...

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

InflaRx N.V.

IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The mid-stage study aimed to evaluate the safety and pharmacokinetic/pharmacodynamic profile of INF904.</li><li>Over four weeks of therapy in patients with HS, the company observed rapid and clinically meaningful reductions in inflammatory signs and substantial reductions in patient-reported pain scores in the study.&nbsp;</li><li>No safety concerns were identified in either of the two patient categories, the company said. &nbsp;</li></ul>InflaRx N.V. (IFRX) announced on Monday that data from a mid-stage trial of its INF904 in certain skin conditions demonstrated positive outcomes, including a reduction in disease severity and pain, which sent shares rallying 62% in the pre-market session.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.inflarx.de/Home/Investors/Press-Releases/11-2025-InflaRx-Reports-Positive-Phase-2a-Data-for-INF904-in-Hidradenitis-Suppurative--HS--and-Chronic-Spontaneous-Urticaria--CSU-.html">studied</a> the experimental drug in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU). It was aimed at evaluating the safety and pharmacokinetics / pharmacodynamics profile of INF904.While Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful, boil-like lumps to form under the skin, Chronic spontaneous urticaria (CSU) is a skin condition characterized by recurrent, itchy hives (wheals) and/or swelling (angioedema) that lasts for six weeks or longer.The company said that the data provide a strong rationale for further development of the drug in both these diseases. &nbsp;<h2 class="st-heading-2">Mid-Stage Trial Results</h2>Over four weeks of therapy in patients with HS, the company observed rapid and clinically meaningful reductions in inflammatory signs and substantial reductions in patient-reported pain scores in the study.&nbsp;In CSU, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients, particularly among those with severe disease. Urticaria Activity Score (UAS) is a patient-reported tool used to measure the severity of chronic hives (urticaria) by assessing the number of hives and the intensity of itch daily.No safety concerns were identified in either of the two patient categories, the company said.The company is now looking forward to initiating a Phase 2b trial in HS in 2026, while also engaging in dialogue with possible collaborators to advance the drug in CSU.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IFRX">IFRX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.IFRX stock is down 50% this year and by about 20% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/grab-holdings-to-take-equity-interest-in-remote-driving-tech-startup/cLPcKrSRE2c">Grab Deepens Autonomous Mobility Push With $60 Million Investment In Vay</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

The company said that the data provide a strong rationale for further development of the drug in Hidradenitis Suppurative and Chronic Spontaneous Urticaria.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.66
Prev Close	$1.72
Open	$1.71
Dividend Yield	0.00%
50-Day Moving Average	$1.87
Beta	1.21
Avg. Volume	500,452.27
PE Ratio	-1.58

52-Week High	$2.95
52-Week Low	$0.7984
Market Capitalization	$244.63M
EPS (Annual)	-$0.7654
Price to Book	1.46
Revenue Per Employee	$509.26

Feed

News

Sentiment

Earnings

Fundamentals

Info

IFRX Fundamentals